Table of Contents Table of Contents
Previous Page  299 / 812 Next Page
Information
Show Menu
Previous Page 299 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S295

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

Acknowledgements

L. Galindo is a Rio-Hortega-fellowship-(ISC-

III; CM14/00111).

http://dx.doi.org/10.1016/j.eurpsy.2016.01.632

EW515

Differential peripherical biomarkers

in severe mental illness

L. Garcia-alvarez

1 ,

, M .

P. Garcia-portilla

1 , 2 , 3 ,

L. Gonzalez-blanco

2 , 3 , L . D

e La Fuente Tomas

2 , C. I

glesias

2 , 4 ,

P. Saiz Martinez

1 , 2 , 3 , J. B

obes

1 , 2 , 3

1

Centro de Investigación Biomédica en Red de Salud Mental,

CIBERSAM G05, Oviedo, Spain

2

Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain

3

Servicio de Salud del Principado de Asturias, SESPA, Oviedo, Spain

4

Servicio de Salud del Principado de Asturias, SESPA, Langreo, Spain

Corresponding author.

Introduction

Patients with schizophrenia and bipolar disorder

have higher rates of medical comorbidities and mortality than gen-

eral population

[1,2] .

Aims

To find severe mental illness biomarkers. Here, we present

the peripherical biological parameters of patients with schizophre-

nia (SCH), bipolar disorder (BD) and healthy subjects (HS).

Methods

Cross-sectional, naturalistic study. Inclusion criteria:

DSM-IV diagnosis of schizophrenia or bipolar disorder; age > 17

years; and written informed consent given.

Results

One hundred and twenty-three SCH, 102 BD and 80

HS. Laboratory tests: red cells, haemoglobin, leukocyte, platelets,

glucose, urea, creatinine, uric acid, cholesterol, HDL-cholesterol,

LDL-cholesterol, triglycerides, GPT, AP, CA, P, FE, insulin, HbA1c

and TSH. Age and gender were used as covariates. There

were differences in: HDL-cholesterol (

P

< 0.0001), triglycerides

(

P

< 0.0001), insulin (

P

< 0.0001), AP (

P

= 0.006) and TSH (

P

= 0.013).

The differences were between SCH and HS (HDL-cholesterol,

triglycerides, insulin, AP and TSH), and, between BD and HS (HDL-

cholesterol, triglycerides, insulin and TSH), but not between SCH

and BD.

Conclusion

There are differences in peripherical biological

parameters between patients with SCH or BD and HS. Biological

biomarkersmay play a role in severemental disorders pathogenesis

[1,2] .

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

References

[1] Physical illness and schizophrenia: a review of the literature.

Acta Psychiatr Scand 2007;116(5):317–33.

[2] Bipolar disorder and comorbidity: increased prevalence and

increased relevance of comorbidity for hospital-based mortal-

ity during a 12.5-year observation period in general hospital

admissions. J Affect Disord 2014;169(170–8).

http://dx.doi.org/10.1016/j.eurpsy.2016.01.633

EW516

Paliperidone palmitate log-acting

injection in patients with psychotic

active clinic: start, change or increase

of dose

A.L. Gonzalez Galdamez

, M.D. Piqueras Acevedo ,

M.R. Raposo Hernández , I. Martínez Pérez , P. Manzur Rojas ,

A. Gil Sánchez , A. Belmar Simo , A. Busaileh Salas ,

F. González Jiménez , R. Sánchez Marín , S. Gómez Bravo ,

C.J. García Bri˜nol , A. Rodriguez Hernandez

Santa Lucia Hospital, Psychiatry, Cartagena-Murcia, Spain

Corresponding author.

The aim is to describe the experience of treatment with Paliperi-

done Palmitate long acting injection (PP) in patients with psychotic

active clinic, whether diagnoses with schizophrenia or in patients

with the first episode psychosis, as well as to reflect the improve-

ment in the control of the symptoms that the patients can improve

increasing the dose.

Methods

We have done a descriptive study of 34 patients hospi-

talized in psychiatry between January and July 2015 for psychotic

active clinic who started treatment with PP or the previous dose

was increased.

Results

91.2% of patients admitted for acute exacerbation of their

usual pathology and 8.8% for a first episode psychosis. In the CGI

scale, all the patients admitted scored as severe or markedly ill;

going mostly mildly ill at discharge. For 55.9% of patients, the treat-

ment was changed to PP, 29.4% of the dose was increased PP and

14.7% antipsychotic treatment was startedwith PP. Among patients

change treatment, the main reason was non-adherence (47.4%).

70.6% of our patients were dischargedwith PP as only antipsychotic

and 29.4% which was discharged with another antipsychotic, the

most frequent association was of PP with Quetiapine (80%).

Conclusions

PP is a highly effective medicament in the treatment

of the schizophrenia that improves the adherence to the treatment,

so in our experience and we consider it a medicament to be consid-

ered in the early stages of the disease. According to our experience

and there are patients who can benefit frombetter control of symp-

toms adjusting the dose individually.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.634

EW517

Inflammatory and metabolic

biomarkers of psychopathological

dimensions of schizophrenia

L. Gonzalez-Blanco

1 , 2 ,

, M .P

. García-Portilla

1 , 2 , 3 ,

L. Garcia-Alvarez

2 , 3 , C . I

glesias

2 , 4 , P . S

aiz

1 , 2 , 3 , A .

Coto

5 ,

J. Bobes

1 , 2 , 3

1

Servicio de Salud del Principado de Asturias, Psiquiatría, Oviedo,

Spain

2

Universidad de Oviedo, Área de Psiquiatría, Oviedo, Spain

3

Centro de Investigación Biomédica en Red de Salud Mental,

CIBERSAM, Oviedo, Spain

4

Servicio de Salud del Principado de Asturias, Psiquiatría, Langreo,

Spain

5

Universidad de Oviedo, Morfología y Biología Celular, Oviedo, Spain

Corresponding author.

Introduction

The concept of schizophrenia as a systemic disease

includes, not only psychosis, but an increase in somatic comor-

bidity and cardiovascular risk

[1] .

Furthermore, it is known the

implication of inflammation in the pathogenesis of schizophrenia

[2] .

Objectives

To determinate potential inflammatory/metabolic

biomarkers of schizophrenia’s dimensions.

Methods

Sample: 36 outpatientswith schizophrenia for less than

11 years, under stable maintenance treatment (mean age [32.25],

males [63.9%]) and their 36 matched controls (age [32.53

±

6.63];

males [72.2%]).

Evaluation

PANSS, Clinical Assessment Interview for Negative

Symptoms(CAINS), Calgary Scale(CDS), CGI, Personal and Social

Performance Scale(PSP). Biomarkers: C-reactive protein (CRP),

homocysteine, glucose, insulin, HOMA-IR (insulin resistance),

cholesterol, HDL, LDL, triglycerides.

Results

Biomarkers differences between groups are shown in

Table 1 . T able 2 s

hows the correlations found after controlling for

Body Mass Index [patients(28.61

±

5.69);controls(24.64

±

3.80);

p = 0.001] and Smoking [patients(52.8%-yes);controls(5.6%-

yes);p = 0.000].